|
FAK Inhibitor GSK2256098 Clinical Trials
1 actively recruiting trial across 1 location
Birmingham, Alabama1 trial
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
University of Alabama at Birmingham Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.